Comera Life Sciences Holdings, Inc. (CMRA)
Comera Life Sciences Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Woburn, MA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,074. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -2843.8%. Its beta of 1.11 implies it has historically moved more than the broad market.
Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms. Currently, the company is progressing two main product candidates: CLS-001, an early-stage "biobetter" designed to treat inflammatory bowel conditions like Crohn's and Ulcerative Colitis, and CLS-002, another preclinical biobetter aimed at diverse oncology indications. Established in 2014, Comera Life Sciences is headquartered in Woburn, Massachusetts.
Comera Life Sciences Holdings, Inc. is most often compared with the following Healthcare names: